Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients

<i>Objective</i>: Anti-CD20-treated patients are at risk of a reduced humoral immune response during the SARS-CoV-2 pandemic. Our aim was to compare the antibody response after two vaccinations with the mRNA vaccines BNT162b2 or mRNA-1273 in patients with multiple sclerosis. <i>Met...

Full description

Bibliographic Details
Main Authors: Helly Hammer, Robert Hoepner, Christoph Friedli, Stephen L. Leib, Franziska Suter-Riniker, Lara Diem, Nicole Kamber, Andrew Chan, Anke Salmen, Christian P. Kamm
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
anti-CD20
COVID-19
multiple sclerosis
pandemic
SARS-CoV-2
vaccination
Online Access:https://www.mdpi.com/2076-393X/10/6/922

Internet

https://www.mdpi.com/2076-393X/10/6/922

Similar Items